Search Results

Business

IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs

IMIDomics Inc. today announced a strategic license and collaboration agreement with the University of Barcelona (UB).

October 11, 2023

·

3 min read

Business

Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases

Twist Bioscience Corporation and IMIDomics, Inc. today announced a multi-program collaboration whereby Twist will utilize its antigen development capabilities and Library of Libraries to conduct antibody discovery activities against targets identified by IMIDomics.

September 27, 2023

·

7 min read

Business

IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases

IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.

October 4, 2023

·

3 min read

Business

IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development

IMIDomics announced today that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company.

December 6, 2023

·

3 min read

Press Releases

IMIDomics, Inc. Appoints Life Sciences Industry Leader Matthias Evers, Ph.D., to Board of Directors

September 18, 2024

·

3 min read

Business

IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team

IMIDomics proudly announces the addition of Dr. Eric Perakslis, a highly accomplished pharmaceutical R&D and digital sciences executive, as Senior Vice President and Chief Technology Officer (CTO).

November 15, 2023

·

3 min read

Business

IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases

IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced an exclusive license agreement with TNAX Biopharma Corporation (TNAX), an innovator in biotechnology.

September 6, 2023

·

5 min read

Business

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

IMIDomics, Inc. announced the formation of an Immunology Advisory Board consisting of a number of scientific and industry luminaries with experience in developing and bringing to market new therapies targeting IMIDs.

December 7, 2022

·

4 min read

Business

IMIDomics™ Announces Scientific and Business Advisory Boards

IMIDomics Inc., a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases, announced the formation and members of its Scientific Advisory Board and Business Advisory Board.

December 7, 2021

·

7 min read

Hand showing money in network. The concept of electronic money.

Business

IMIDomics, IgGenix and neuro42 Close Series A Rounds Worth Millions

Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.

July 28, 2021

·

2 min read

·

Brandon May